var data={"title":"Pyridostigmine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pyridostigmine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6878?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pyridostigmine-drug-information\" class=\"drug drug_general\">see &quot;Pyridostigmine: Drug information&quot;</a> and <a href=\"topic.htm?path=pyridostigmine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pyridostigmine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215907\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Mestinon;</li>\n      <li>Regonol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215908\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Mestinon;</li>\n      <li>Mestinon-SR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061685\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidote, Neuromuscular Blocking Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Cholinergic Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11444893\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Myasthenic syndrome; congenital:</b> Limited data available: Oral: 1 mg/kg/dose every 4 hours; maximum daily dose: 7 mg/kg/<b>day</b> divided in 5-6 doses (Lorenzoni, 2012)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061679\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=pyridostigmine-drug-information\" class=\"drug drug_general\">see &quot;Pyridostigmine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> All pediatric dosing recommendations based on immediate release product formulations. Dosage should be individualized based on patient response.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Myasthenic syndromes, congenital:</b> Limited data available: Infants, Children, and Adolescents: Oral: 1 mg/kg/dose every 4 hours; usual range: 4 to 5 mg/kg/day in 4 to 6 divided doses; maximum daily dose: 7 mg/kg/<b>day</b> divided in 5-6 doses (Kleigman, 2011; Lorenzoni, 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Myasthenia gravis, autoimmune (juvenile):</b> Limited data available: Infants, Children, and Adolescents: <b>Note:</b> Dosage should be adjusted such that larger doses administered prior to time of greatest fatigue.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 1 mg/kg/dose every 4-6 hours; maximum daily dose: 7 mg/kg/<b>day</b> divided in 5-6 doses; usual daily dose: 600 mg/<b>day</b>; doses as high as 1500 mg/<b>day</b> have been used (Andrews, 1998; Maggi, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM, IV:  0.05-0.15 mg/kg/dose; maximum  dose: 10 mg (Kleigman, 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Reversal of nondepolarizing neuromuscular blocker:</b> Limited data available: Infants, Children, and Adolescents: IM, IV: 0.1-0.25 mg/kg/dose (Kleigman, 2007). <b>Note:</b> Give atropine or glycopyrrolate immediately prior to minimize side effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Vincristine-induced neurotoxicity:</b> Limited data available: Children &ge;2 years and Adolescents: Oral: 3 mg/kg/day divided in 2 doses, given with pyridoxine for 3 weeks; dosing based on a case series of four children (age: 2-13 years) receiving vincristine for treatment of ALL (Akbayram, 2010) and a 2-year old receiving vincristine for a cervical synovial sarcoma (Muller, 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Myasthenia gravis: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Immediate release: Highly individualized dosing ranges: 60-1500 mg/day, usually 600 mg/day divided into 5-6 doses, spaced to provide maximum relief </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Sustained release formulation: Highly individualized dosing ranges: 180-540 mg once or twice daily (doses separated by at least 6 hours); <b>Note:</b> Most clinicians reserve sustained release dosage form for bedtime dose only. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM or slow IV push: To supplement oral dosage pre- and postoperatively during labor and postpartum, during myasthenic crisis, or when oral therapy is impractical: ~1/30th of oral dose; observe patient closely for cholinergic reactions</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV infusion: To supplement oral dosage pre- and postoperatively, during labor and postpartum, during myasthenic crisis, or when oral therapy is impractical: Initial: 2 mg/hour with gradual titration in increments of 0.5-1 mg/hour, up to a maximum rate of 4 mg/hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Reversal of nondepolarizing neuromuscular blocker:</b> IV: 0.1-0.25 mg/kg/dose; 10-20 mg is usually sufficient (full recovery usually occurs &le;15 minutes, but &ge;30 minutes may be required)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Soman nerve gas exposure; pretreatment (military use):</b> Oral: 30 mg every 8 hours beginning several hours before exposure; discontinue at first sign of nerve agent exposure, then begin atropine and pralidoxime </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosage adjustment in renal impairment:</b> There are no dosage adjustments are provided in the manufacturer&rsquo;s labeling; however, lower doses may be required due to prolonged elimination; dosage titration should be based on drug effects.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment in hepatic impairment:</b> There are no dosage adjustments are provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215882\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as bromide: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Regonol: 10 mg/2 mL (2 mL) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Syrup, Oral, as bromide: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mestinon: 60 mg/5 mL (473 mL) [contains alcohol, usp, brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40, sodium benzoate; raspberry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as bromide: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mestinon: 60 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 60 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release, Oral, as bromide: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mestinon: 180 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 180 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215867\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061689\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Swallow sustained release tablets whole, do not chew or crush </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Parenteral: May administer IM or as a direct IV slowly over 2-4 minutes; patients receiving large parenteral doses should be pretreated with atropine </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215902\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from moisture.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Military use: Store between 2&deg;C and 8&deg;C (36&deg;F to 46&deg;F); protect from light. Discard 3 months after issue. Do not dispense after removal from the refrigerator for more than a total of 3 months.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061688\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Mestinon&reg;: Treatment of myasthenia gravis (FDA approved in adults); has also been used for treatment of vincristine induced neurotoxicity, congenital myasthenic syndrome, and pretreatment for Soman nerve gas exposure (military use only)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Regonol&reg;: Reversal agent for effects of nondepolarizing neuromuscular blocking agents (FDA approved in adults); has also been used for treatment of myasthenia gravis   </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215957\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pyridostigmine may be confused with physostigmine </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Regonol may be confused with Reglan, Renagel</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215954\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Bradycardia (transient), chest tightness, decreased heart rate, increased blood pressure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Confusion, depressed mood, disturbed sleep, drowsiness, headache, hyperesthesia, hypertonia, lack of concentration, lethargy, localized warm feeling, numbness of tongue, tingling of extremities, twitching, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia, diaphoresis, skin rash, xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal cramps, abdominal pain, bloating, borborygmi, diarrhea, flatulence, increased peristalsis, nausea, salivation, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Dysmenorrhea, urinary frequency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Fasciculations, muscle cramps, myalgia, neck pain, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Amblyopia, eye pain, lacrimation, miosis, visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Acute bronchitis (exacerbation), epistaxis, exacerbation of asthma, increased bronchial secretions</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Fecal incontinence, loss of consciousness, pallor (postsyncopal), stiffness (arms or upper torso), thrombophlebitis, urinary incontinence</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215888\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to pyridostigmine, anticholinesterase agents, or any component of the formulation; mechanical intestinal or urinary obstruction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for anticholinergic muscle stimulants is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215871\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cholinergic effects: Symptoms of excess cholinergic activity may occur (eg, salivation, sweating, urinary incontinence). Overdosage may result in cholinergic crisis (eg, muscle weakness), which must be distinguished from myasthenic crisis; discontinue immediately in the presence of cholinergic crisis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: May occur; have atropine and epinephrine ready to treat hypersensitivity reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with bradycardia or other cardiac arrhythmias.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Glaucoma: Use with caution; additive effect with antiglaucoma drugs may cause or exacerbate problems with night vision.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; initial lower doses may be needed; titrate to effect.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disease: Use with extreme caution in patients with asthma, bronchospastic disease, or COPD.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bromide sensitivity: Use with caution in patients with bromide sensitivity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatrics: Injection not indicated for use in neonates; may contain benzyl alcohol which has been associated with &quot;gasping syndrome&quot; in neonates.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection: Must be administered by trained personnel; use of peripheral nerve stimulation to monitor neuromuscular function recovery and continuous patient observation until recovery of normal respiration is recommended. To counteract anticholinergic effects, use of glycopyrrolate or atropine sulfate simultaneously with or prior to administration is recommended. May contain benzyl alcohol which has been associated with &quot;gasping syndrome&quot; in neonates.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral: Adequate facilities should be available for cardiopulmonary resuscitation when testing and adjusting dose for myasthenia gravis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Inadequate reversal of nondepolarizing muscle relaxants: Inadequate reversal induced by nondepolarizing muscle relaxants is possible; manage with manual or mechanical ventilation until recovery is adequate (additional doses not recommended). Failure to produce prompt (within 30 minutes) reversal of neuromuscular blockade may occur in the presence of extreme debilitation, carcinomatosis, or with concomitant use of certain broad-spectrum antibiotics, or anesthetic agents and other drugs which enhance neuromuscular blockade or cause respiratory depression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Military use: Only for pretreatment for exposure to Soman; discontinue pyridostigmine at the first sign of Soman exposure (do not administer pyridostigmine after Soman exposure); atropine and pralidoxime must be administered after Soman exposure (pyridostigmine pretreatment offers no benefit against Soman unless atropine and pralidoxime are administered once symptoms of poisoning appear). Use in conjunction with protective garments, including gas mask, hood and overgarments.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26080235\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Neonates of myasthenic mothers may have transient difficulties in swallowing, sucking, and breathing; use of pyridostigmine may be of benefit; use edrophonium test to assess neonate with these symptoms. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299967\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215875\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12752&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Amifampridine. Amifampridine side effects may also be increased. Amifampridine may enhance the therapeutic effect of Acetylcholinesterase Inhibitors. Acetylcholinesterase inhibitor side effects may also be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: Acetylcholinesterase Inhibitors may diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benoxinate: Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Benoxinate. Specifically, the effects of benoxinate may be prolonged. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: Acetylcholinesterase Inhibitors may enhance the bradycardic effect of Beta-Blockers. <b> Exceptions: </b>Levobunolol; Metipranolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholinergic Agonists: Acetylcholinesterase Inhibitors may enhance the adverse/toxic effect of Cholinergic Agonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyridamole: May diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methocarbamol: May diminish the therapeutic effect of Pyridostigmine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents (Nondepolarizing): Acetylcholinesterase Inhibitors may diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Succinylcholine: Acetylcholinesterase Inhibitors may increase the serum concentration of Succinylcholine.  Management: Consider alternatives to this combination due to a risk of prolonged neuromuscular blockade.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215878\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B/C (manufacturer dependent) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215891\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events have not been observed in animal reproduction studies. Pyridostigmine may cross the placenta (Buckley 1968). Use of pyridostigmine may be continued during pregnancy for the treatment of myasthenia gravis (Norwood 2013; Skie 2010) and its use should be continued during labor (Norwood 2013). Transient neonatal myasthenia gravis may occur in 10% to 20% of neonates due to placental transfer of maternal antibodies (Skie 2010; Varner 2013).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061684\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Muscle strength, heart rate, respiration; vital capacity; observe for cholinergic reactions, particularly when administered IV</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215870\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits destruction of acetylcholine by acetylcholinesterase which facilitates transmission of impulses across neuromuscular junction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215887\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Recovery from vincristine neurotoxicity: Onset of action: 1 to 2 weeks (Akbayram 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Myasthenia gravis: Oral: Within 30 minutes (Maggi 2011); IM: 15 to 30 minutes; IV: Within 2 to 5 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Oral: 3 to 4 hours in the daytime (Maggi 2011); IM, IV: 2 to 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Very poor</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 0.53 to 1.76 L/kg (Aquilonius 1986)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein Binding: None (Aquilonius 1986)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic and at tissue site by cholinesterases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: 10% to 20% (Aquilonius 1986)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: 1 to 2 hours; renal failure: ~6 hours (Aquilonius 1986)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: ~1.5 hours (Aquilonius 1980)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: Oral: 1 to 2 hours (Aquilonius 1986)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (80% to 90% as unchanged drug) (Aquilonius 1986)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215890\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Regonol Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/2 mL (2 mL): $32.08</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Syrup</b> (Mestinon Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg/5 mL (473 mL): $1,404.02</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (Mestinon Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">180 mg (30): $983.57</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (Pyridostigmine Bromide ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">180 mg (30): $744.23</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Mestinon Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (100): $1,728.56</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Pyridostigmine Bromide Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (100): $127.50</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215893\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Amygra (PK);</li>\n      <li>Antilon (TW);</li>\n      <li>Astinon (PH);</li>\n      <li>Brostagin (PL);</li>\n      <li>Distinon (IN);</li>\n      <li>Dosmin (KR);</li>\n      <li>Dostimid (BD);</li>\n      <li>Kalimin (UA);</li>\n      <li>Kalymin (BG, DE, EE, LV, RU, TR);</li>\n      <li>Meshanon (VN);</li>\n      <li>Mestinon (AE, AR, AT, AU, BB, BE, BH, BM, BR, BS, BZ, CH, CL, CO, CY, CZ, DK, EG, ES, FI, FR, GB, GH, GR, GY, HK, HR, HU, ID, IE, IL, IQ, IR, IT, JM, JO, KR, KW, LB, LK, LU, LY, MT, MX, MY, NO, OM, PE, PH, PL, PT, PY, QA, SA, SE, SG, SI, SK, SR, SY, TH, TR, TT, TW, TZ, UG, UY, VE, YE, ZM);</li>\n      <li>Mestinon Retard (NL);</li>\n      <li>Mestinon Timespan (BB);</li>\n      <li>Pyrido (LK);</li>\n      <li>Pyrimine (TH);</li>\n      <li>Pyrinol (KR);</li>\n      <li>Pyrinon (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyridostigmine-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Akbayram S, Akgun C, Do&#287;an M, et al, &quot;Use of Pyridoxine and Pyridostigmine in Children With Vincristine-Induced Neuropathy,&quot; <i>Indian J Pediatr</i>, 2010, 77(6):681-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyridostigmine-pediatric-drug-information/abstract-text/20532679/pubmed\" target=\"_blank\" id=\"20532679\">20532679</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyridostigmine-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Andrews PI, &quot;A Treatment Algorithm for Autoimmune Myasthenia Gravis in Childhood,&quot; <i>Ann N Y Acad Sci</i>, 1998, 841:789-802.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyridostigmine-pediatric-drug-information/abstract-text/9668332/pubmed\" target=\"_blank\" id=\"9668332\">9668332</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aquilonius SM and Hartvig P, &quot;Clinical Pharmacokinetics of Cholinesterase Inhibitors,&quot; <i>Clin Pharmacokinet</i>, 1986, 11(3):236-49.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyridostigmine-pediatric-drug-information/abstract-text/3524957/pubmed\" target=\"_blank\" id=\"3524957\">3524957</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyridostigmine-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 19th ed. Philadelphia, PA: Saunders Elsevier;2011. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lorenzoni PJ, Scola RH, Kay CS, et al, &quot;Congenital Myasthenic Syndrome: A Brief Review,&quot; <i>Pediatr Neurol</i>, 2012, 46(3):141-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyridostigmine-pediatric-drug-information/abstract-text/22353287/pubmed\" target=\"_blank\" id=\"22353287\">22353287</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maggi L and Mantegazza R, &quot;Treatment of Myasthenia Gravis: Focus on Pyridostigmine,&quot; <i>Clin Drug Investig</i>, 2011, 31(10):691-701.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyridostigmine-pediatric-drug-information/abstract-text/21815707/pubmed\" target=\"_blank\" id=\"21815707\">21815707</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    M&uuml;ller L, Kramm CM, Tenenbaum T, et al, &quot;Treatment of Vincristine-Induced Bilateral Ptosis With Pyridoxine and Pyridostigmine,&quot; <i>Pediatr Blood Cancer</i>, 2004, 42(3):287-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyridostigmine-pediatric-drug-information/abstract-text/14752870/pubmed\" target=\"_blank\" id=\"14752870\">14752870</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12752 Version 113.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F215907\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F215908\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1061685\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11444893\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1061679\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F215882\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F215867\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1061689\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F215902\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1061688\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F215957\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F215954\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F215888\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F215871\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26080235\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299967\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F215875\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F215878\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F215891\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1061684\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F215870\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F215887\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F215890\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F215893\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12752|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pyridostigmine-drug-information\" class=\"drug drug_general\">Pyridostigmine: Drug information</a></li><li><a href=\"topic.htm?path=pyridostigmine-patient-drug-information\" class=\"drug drug_patient\">Pyridostigmine: Patient drug information</a></li></ul></div></div>","javascript":null}